Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: A safe and effective combination

Melanoma Research

Volumn 27, Issue 5, 2017, Pages 485-491

  Aboudaram, Amélie ^a   Modesto, Anouchka ^a   Chaltiel, Léonor ^b   Gomez Roca, Carlos ^c   Boulinguez, Serge ^c   Sibaud, Vincent ^c   Delord, Jean Pierre ^c   Chira, Ciprian ^a   Delannes, Martine ^a   Moyal, Elizabeth ^a   Meyer, Nicolas ^c  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b Claudius Regaud Institute   (France)

^c SERVICE DE PNEUMOLOGIE   (France)

Author keywords

Abscopal effect; Anti programmed death 1; Immunotherapy; Melanoma; Radiation therapy

Indexed keywords

NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; ANTINEOPLASTIC AGENT; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; AGED; ARTICLE; ASTHENIA; BRAIN METASTASIS; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; ENCEPHALITIS; FEMALE; FOLLOW UP; HEPATITIS; HUMAN; KIDNEY DYSFUNCTION; LUNG DISEASE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; RETROSPECTIVE STUDY; SKIN DISEASE; THYROID DISEASE; TREATMENT RESPONSE; WEGENER GRANULOMATOSIS; MELANOMA; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; YOUNG ADULT;

EID: 85032820225     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000386     Document Type: Article

References (23)

1. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320-330.
2. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372: 2006-2017.
3. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521-2532.
4. Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, Formenti SC. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 2004; 58: 862-870.
5. Levy A, Chargari C, Marabelle A, Perfettini JL, Magne N, Deutsch E. Can immunostimulatory agents enhance the abscopal effect of radiotherapys Eur J Cancer 2016; 62: 36-45.
6. Levy A, Massard C, Soria JC, Deutsch E. Concurrent irradiation with the antiprogrammed cell death ligand-1 immune checkpoint blocker durvalumab: Single centre subset analysis from a phase 1/2 trial. Eur J Cancer 2016; 68: 156-162.
7. Ahmed KA, Stallworth DG, Kim Y, Johnstone PA, Harrison LB, Caudell JJ, et al. Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. Ann Oncol 2016; 27: 434-441.
8. Bang A, Wilhite TJ, Pike LRG, Cagney DN, Aizer AA, Taylor A, et al. Multicenter Evaluation of the tolerability of combined treatment with PD-1 and CTLA-4 immune checkpoint inhibitors and palliative radiation therapy. Int J Radiat Oncol Biol Phys 2017; 98: 344-351.
9. Sibaud V, David I, Lamant L, Resseguier S, Radut R, Attal J, et al. Acute skin reaction suggestive of pembrolizumab-induced radiosensitization. Melanoma Res 2015; 25: 555-558.
10. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-1059.
11. Demaria S, Golden EB, Formenti SC. Role of local radiation therapy in cancer immunotherapy. JAMA Oncol 2015; 1: 1325-1332.
12. Wang C, Thudium KB, Han M, Wang XT, Huang H, Feingersh D, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res 2014; 2: 846-856.
13. Liang H, Deng L, Chmura S, Burnette B, Liadis N, Darga T, et al. Radiationinduced equilibrium is a balance between tumor cell proliferation and T cellmediated killing. J Immunol 2013; 190: 5874-5881.
14. Dalgleish AG. Rationale for combining immunotherapy with chemotherapy. Immunotherapy 2015; 7: 309-316.
15. Michot JM, Mazeron R, Dercle L, Ammari S, Canova C, Marabelle A, et al. Abscopal effect in a Hodgkin lymphoma patient treated by an antiprogrammed death 1 antibody. Eur J Cancer 2016; 66: 91-94.
16. Formenti SC, Demaria S. Systemic effects of local radiotherapy. Lancet Oncol 2009; 10: 718-726.
17. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012; 366: 925-931.
18. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206.
19. Kiess AP, Wolchok JD, Barker CA, Postow MA, Tabar V, Huse JT, et al. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys 2015; 92: 368-375.
20. Schaue D, Ratikan JA, Iwamoto KS, McBride WH. Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys 2012; 83: 1306-1310.
21. Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, Demaria S. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009; 15: 5379-5388.
22. Hecht M, Zimmer L, Loquai C, Weishaupt C, Gutzmer R, Schuster B, et al. Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients. Ann Oncol 2015; 2: 1238-1244.
23. Patel KR, Chowdhary M, Switchenko JM, Kudchadkar R, Lawson DH, Cassidy RJ, et al. BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis. Melanoma Res 2016; 26: 387-394.